Therapeutic agent for glaucoma

• US 5,547,993 A
• Filed: 10/24/1995
• Issued: 08/20/1996
• Est. Priority Date: 10/24/1995
• Status: Expired due to Fees

• Current Assignee: Mitsubishi Chemical Corporation (Mitsubishi Chemical Group Corp.)
• Original Assignee: Mitsubishi Chemical Corporation (Mitsubishi Chemical Group Corp.)
• Inventors: Miki, Hirohiko
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US08/547,541
• Time in Patent Office: 301 Days
• Field of Search: 514/648, 514/913
• US Class Current: 514/648
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377

Abstract

The present invention provides a novel drug for treating glaucoma. The present invention relates to a therapeutic agent for glaucoma which comprises an aminoalkoxybibenzyl represented by the formula (I): ##STR1## or a hydrate or pharmaceutically acceptable salt thereof as an active ingredient.

Claims

1. A method of treating glaucoma which comprises administering to a patient in need thereof, an effective amount of a compound represented by the formula (I):

##STR3## or a hydrate or pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein said compound is a pharmaceutically acceptable salt selected from the group consisting of mineral acid salts and organic acid salts.

3. The method according to claim 2, wherein the mineral acid salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate and phosphate.

4. The method according to claim 2, wherein the organic acid salt is selected from the group consisting of acetate, maleate, fumarate, citrate, oxalate, succinate, tartarate, malate, mandelate, methanesulfonate, p-toluenesulfonate and 10-camphor sulfonate.

5. The method according to claim 1, wherein said compound is administered in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable additive.

6. The method according to claim 5, wherein the pharmaceutical composition comprises said compound and at least one pharmaceutically acceptable additive selected from the group consisting of excipients, disintegrators or disintegrating aids, binders, lubricants, coating agents, pigments, diluents, bases, dissolving agents or solubilizers, isotonic agents, pH regulators, stabilizers, propellants and adhesives.

7. The method according to claim 1, wherein said compound is administered orally.

8. The method according to claim 1, wherein said compound is administered parenterally.

9. The method according to claim 1, wherein said compound is administered percutaneously.

10. The method according to claim 1, wherein said compound is administered transmucosally.

11. The method according to claim 1, wherein said compound is administered in a daily dose of 15-300 mg.

12. The method according to claim 1, wherein said compound is administered in a daily dose of 50-200 mg.